Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kirill Kosilov, Sergey Loparev, Irina Kuzina, Olga Shakirova, Natalya Zhuravskaya & Alexandra Lobodenko. (2017) The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms. The Aging Male 20:1, pages 39-44.
Read now
Read now
Articles from other publishers (11)
Antonio La Torre, Caterina Palleria, Irene Tamanini, Andrea Scardigli, Tommaso Cai, Manuela Colosimo, Lucia Muraca, Vincenzo Rania, Davida Mirra, Alessandro Casarella, Gianmarco Marcianò, Giovambattista De Sarro & Luca Gallelli. (2021) Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors. Uro 1:3, pages 82-98.
Crossref
Crossref
Pedro Abreu-Mendes, João Silva & Francisco Cruz. (2020) Pharmacology of the lower urinary tract: update on LUTS treatment. Therapeutic Advances in Urology 12, pages 175628722092242.
Crossref
Crossref
Mohammad Khalid Zia, Tooba Siddiqui, Syed Saqib Ali, Haseeb Ahsan & Fahim Halim Khan. (2019) Deciphering the binding of dutasteride with human alpha-2-macroglobulin: Molecular docking and calorimetric approach. International Journal of Biological Macromolecules 133, pages 1081-1089.
Crossref
Crossref
Emeka I. Udeh, Chimaobi G. Ofoha, David A. Adewole & Ikenna I. Nnabugwu. (2016) A cost effective analysis of fixed-dose combination of dutasteride and tamsulosin compared with dutasteride monotherapy for benign prostatic hyperplasia in Nigeria: a middle income perspective; using an interactive Markov model. BMC Cancer 16:1.
Crossref
Crossref
Konstantinos Dimitropoulos & Stavros Gravas. (2015) Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia. Therapeutic Advances in Urology 8:1, pages 19-28.
Crossref
Crossref
Marcus J. Drake, Roman Sokol, Karin Coyne, Zalmai Hakimi, Jameel Nazir, Julie Dorey, Monique Klaver, Klaudia Traudtner, Isaac A. Odeyemi, Matthias Oelke & Philip van Kerrebroeck. (2016) Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study. BJU International 117:1, pages 165-172.
Crossref
Crossref
Dean S Elterman, Bilal Chughtai, Steven A Kaplan & Jack Barkin. (2012) Combination treatment with tamsulosin and dutasteride for benign prostatic hyperplasia. Aging Health 8:6, pages 555-565.
Crossref
Crossref
Bilal Chughtai, Dean S. Elterman, Richard Lee, Alexis E. Te & Steven A. Kaplan. (2012) Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia. Therapeutic Advances in Urology 4:5, pages 267-272.
Crossref
Crossref
Gillian M. Keating. (2012) Dutasteride/Tamsulosin. Drugs & Aging 29:5, pages 405-419.
Crossref
Crossref
Dean S. Elterman, Jack Barkin & Steven A. Kaplan. (2012) Optimizing the management of benign prostatic hyperplasia. Therapeutic Advances in Urology 4:2, pages 77-83.
Crossref
Crossref
Hoon ChoiYoung Seop ChangByung Hun ParkDong Hoon KoYoung Joon MoonJin Bum Kim. (2012) Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor. Korean Journal of Andrology 30:1, pages 45.
Crossref
Crossref